Navigation Links
Hebrew University professor's work leads to FDA approval for product
Date:3/26/2009

Jerusalem, March 25, 2009 A material developed at the Hebrew University of Jerusalem that is designed to prevent adhesions (scar tissue) following surgery has led to approval by the U.S. Food and Drug Administration (FDA) of a product for use in pediatric cardiac surgery patients.

The product is the result of Prof. Daniel Cohn's invention of novel, tailor-made, biodegradable polymers for the prevention of post-surgical adhesions. SyntheMed Inc. of Iselin, N.J. in the U.S., received the technology from Yissum the Technology Transfer Company of the Hebrew University, and has now obtained FDA pre-market approval for the first product, REPEL-CV Adhesion Barrier, for use in pediatric patients (21 and younger) who are likely to need secondary open heart surgery.

The generation of adhesions following heart surgery is of special concern, since they may affect cardiac function. Furthermore, in the frequent cases where repeat operations are required, adhesions obscure cardiac landmarks, making the procedure potentially life-threatening to the patient due to inadvertent vascular or cardiac injury.

In the U.S., there are 350,000 to 400,000 children with congenital cardiac abnormalities. Many neonatal and infant patients must undergo multiple surgeries before their defect is corrected, while other children require additional operations as they grow. The REPEL-CV Adhesion Barrier product gives physicians another tool to help decrease the complications that may occur during these surgeries. .

"I am very excited that the long process that started several years ago in our laboratory at the Institute of Chemistry of the Hebrew University with the design and synthesis of a family of biodegradable polymers was recently approved by the FDA," said Prof. Cohn.

"This biomedical product harnessed the unique properties of a family of custom-made, biodegradable polymers aimed at treating a large, incredibly widespread clinical problem, which pertains to all surgeries: post-operative adhesions. Each and every surgery conducted inevitably results in post-surgical adhesions, and the polymeric film developed at the Hebrew University allows us to minimize those adhesions."

The approval by the FDA came after its approval in Europe and Canada.

Receiving the approval of the different regulatory agencies was the result of the work of a large team. It started with the research conducted by Prof. Cohn and his students, who largely contributed to this endeavour, and continued with the work done at SyntheMed Inc. that developed the product and brought it to the clinic.

"I would like to thank each and all of them and acknowledge their pivotal contribution to the success of this project, all along the journey," said Prof. Cohn.

Prof. Cohn's work on the polymers led to his receiving first prize last year in the Kaye Awards for Innovation, given annually to encourage faculty, staff, and students of the Hebrew University to develop innovative methods and inventions with good commercial potential.


'/>"/>

Contact: Jerry Barach
jerryb@savion.huji.ac.il
972-258-82904
The Hebrew University of Jerusalem
Source:Eurekalert  

Related biology news :

1. Hebrew University scientists reveal mechanism that triggers differentiation of embryo cells
2. Scent on demand: Hebrew University scientists enhance the scent of flowers
3. Hebrew University develops novel approach for treating mitochondrial disorders
4. Hebrew University study opening new route for combating viruses
5. Electronic structure of DNA revealed for 1st time by Hebrew University and collaborating researchers
6. Five young Hebrew University scientists win first competitive EU grants
7. Hebrew SeniorLife researchers search for aging, osteoporosis genes
8. Antioxidant to retard wrinkles discovered by Hebrew University researcher
9. The University of Miami receives grants from Royal Caribbean Cruises Ltd.s Ocean Fund
10. University researchers to develop coatings that kill superbugs
11. K-State researchers work with university in Ghana to create biofuels from native tree seeds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Hebrew University professor's work leads to FDA approval for product
(Date:2/13/2017)... Feb. 13, 2017 Former 9/11 Commission border ... Committee, Janice Kephart of Identity Strategy Partners, ... Donald Trump,s "Executive Order: Protecting the Nation From ... 2017):  "As President Trump,s ,Travel Ban, Executive ... now essentially banned the travel ban, it is important ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):
(Date:2/28/2017)... Norwood, MA (PRWEB) , ... February 28, 2017 ... ... successful clinical trials, yet requires extensive coordination and expertise. Colpitts Clinical Trial ... is celebrating 15 years of meeting this unique need within the biotechnology and ...
(Date:2/28/2017)... ... February 28, 2017 , ... GigaGen Inc ., a ... repertoires, today announced a strategic partnership with Trianni, Inc. , a biotechnology ... antibodies. The partnership will use GigaGen technology to discover immuno-oncology antibody therapeutics through ...
(Date:2/28/2017)... 28, 2017 Sangamo Therapeutics, Inc. (NASDAQ: ... reported its fourth quarter and full year 2016 ... this year we rebranded our company as Sangamo ... genomic therapies using our industry leading platform technologies ... cell therapy," said Sandy Macrae , CEO ...
(Date:2/27/2017)... VANCOUVER , Feb. 27, 2017 /PRNewswire/ - InMed Pharmaceuticals, ... to their expiry on Friday, February 24, 2017 a total ... a price of $0.13 per common share. Proceeds from the ... were issued from InMed,s Treasury.   ... "We are grateful for this expression ...
Breaking Biology Technology: